• No results found

GA 101003666 Start date: 01/04/20 End Date: 31/03/22

N/A
N/A
Protected

Academic year: 2022

Share "GA 101003666 Start date: 01/04/20 End Date: 31/03/22"

Copied!
2
0
0

Loading.... (view fulltext now)

Full text

(1)

GA 101003666 Start date: 01/04/20 End Date: 31/03/22

Project Title OPENCORONA

WP number,

deliverable number, and Title

WP 3

3.1 Established assay for determination of neutralizing antibodies to SARS-COV-2 that can be used to test mouse and rabbit sera

Responsible partner

name and contact Partner number: 3

Organisation: Public Health Agency of SWEDEN Name: Ali Mirazimi

Email: Ali.Mirazimi@folkhalsomyndigheten.se Nature

R-Report P-Prototype D-Demonstrator O=-Other

R

Dissemination level PU-public

PP-restricted to otherprogramme participants

RE-restricted to a group of partners CO-only for

consortium members

PU

Delivery Month

Planned M 3

Actual delivery date

(dd/mm/yy) 16/07/2020

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003666

Ref. Ares(2020)4616375 - 04/09/2020

(2)

Description of deliverable

COMPLETED

Detection of SARS-CoV-2 Neutralizing antibodies Purpose

Detection of neutralizing antibodies against SARS-CoV-2 in serum.

Virus: SARS-CoV-2 Controls

• Negative control: Negative serum in equal dilution as the sample.

• Cell control: Cell culture medium alone

• Positive control: SARS-CoV2 Virus.

Procedure

• Vero E6 cells are plated in a 96 well plate. Plate 1.5x104cells/well and incubate in 37°C, 5% CO2 over night.

• Cells are ready to be used when 90-95% confluence is reached.

• Dilute the serum sample and negative serum control

o Make 2-fold serial dilutions of the serum samples and negative serum control.

o All dilutions are made in quadruplicates

• On a round bottom 96 well plate add 55 ul of : o diluted serum samples to designated wells

o diluted negative control serum to designated wells

o only cell culture medium to designated wells (cell control) o only cell culture medium to designated wells (positive control)

• In a total of 55 ul, SARS-CoV-2 virus (500 pfu) to each designated well o serum samples and positive control wells

• Add 55 ul of medium to designated wells o negative control serum and cell control

• Incubate plate 1 hr in 37°C, 5% CO2

• After 1 hr, remove cell culture medium from the Vero E6 plate

• add 100 ul of the serum/virus mix as well as the negative and positive controls to designated wells on the cell plate

• Incubate in 37°C, 5% CO2for 3 days.

• The cytopathogenic effect for each well is investigated

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003666

References

Related documents

Regeringen och SKR kommer för 2020 ingå ett antal överenskommelser på centrala områden, som på olika sätt bidrar till hälso- och sjukvårdspolitiska mål på olika områden.

The risk and management plan is established according to the OPENCORONA project Grant Agreement no 101003666 WP8 in order to provide a plan for the threats and opportunities that

Expansion of SARS-CoV-2- specific Antibody-secreting Cells 1 and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients (Submitted to

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003666.

Preliminary data from the ferret study show that the OC2 and OC12 (N) constructs induce T cell responses that can limit virus replication. This suggests that T cells alone can limit

The established model has thereafter been used to evaluate protection of infection after vaccination with the selected SARS-CoV-2 vaccine candidate/s. Infection Protocols

WP6 D6.2 D24 Completion of the GLP toxicity study, month Completed toxicological evaluation according to GLP of the vaccine candidate Adlego Report Public 31 Mar 2021 Pending. WP6

Beslut om bygglov upphör att gälla, om åtgärden inte har påbörjats inom två år och avslutats inom fem år från den dag då beslutet vinner laga kraft enligt 9 kap 43 §